RESUMO
PURPOSE: The objective of the current study is to investigate the hypothesis that bioactive terpenoids and flavonoids of Ginkgo biloba extract (GBE) induce human hepatic drug metabolizing enzymes (DMEs) and transporters through the selective activation of pregnane X receptor (PXR), constitutive androstane receptor (CAR), and aryl hydrocarbon receptor (AhR). METHODS: Human primary hepatocyte (HPH), and HepG2 cells are used as in vitro models for enzyme induction and nuclear receptor activation studies. A combination of real-time RT-PCR, transient transfection, and cell-based reporter assays were employed. RESULTS: In human primary hepatocytes, real-time PCR analysis showed induction of CYP2B6, CYP3A4, UGT1A1, MDR1, and MRP2 by EGb 761, ginkgolide A (GA) and ginkgolide B (GB), but not by bilobalide (BB) or the flavonoids (quercetin, kaempferol and tamarixetin) of GBE. Cell-based reporter assays in HepG2 revealed that GA and GB are potent activators of PXR; quercetin and kaempferol activate PXR, CAR, and AhR, whereas BB exerts no effects on these xenobiotic receptors. Notably, the flavonoids induced the expression of UGT1A1 and CYP1A2 in HepG2 cells but not in HPH. CONCLUSION: Our results indicate that terpenoids and flavonoids of GBE exhibit differential induction of DMEs through the selective activation of PXR, CAR, and AhR.
Assuntos
Transportadores de Cassetes de Ligação de ATP/biossíntese , Enzimas/biossíntese , Flavonoides/farmacologia , Hepatócitos/efeitos dos fármacos , Extratos Vegetais/farmacologia , Receptores de Hidrocarboneto Arílico/efeitos dos fármacos , Receptores Citoplasmáticos e Nucleares/efeitos dos fármacos , Receptores de Esteroides/efeitos dos fármacos , Terpenos/farmacologia , Fatores de Transcrição/efeitos dos fármacos , Subfamília B de Transportador de Cassetes de Ligação de ATP , Membro 1 da Subfamília B de Cassetes de Ligação de ATP/biossíntese , Transportadores de Cassetes de Ligação de ATP/genética , Hidrocarboneto de Aril Hidroxilases/biossíntese , Fatores de Transcrição Hélice-Alça-Hélice Básicos , Linhagem Celular Tumoral , Células Cultivadas , Receptor Constitutivo de Androstano , Citocromo P-450 CYP2B6 , Citocromo P-450 CYP3A/biossíntese , Indução Enzimática , Enzimas/genética , Flavonoides/isolamento & purificação , Genes Reporter , Ginkgo biloba , Glucuronosiltransferase/biossíntese , Hepatócitos/enzimologia , Humanos , Proteína 2 Associada à Farmacorresistência Múltipla , Proteínas Associadas à Resistência a Múltiplos Medicamentos/biossíntese , Oxirredutases N-Desmetilantes/biossíntese , Extratos Vegetais/química , Receptor de Pregnano X , RNA Mensageiro/biossíntese , Receptores de Hidrocarboneto Arílico/genética , Receptores de Hidrocarboneto Arílico/metabolismo , Receptores Citoplasmáticos e Nucleares/genética , Receptores Citoplasmáticos e Nucleares/metabolismo , Receptores de Esteroides/genética , Receptores de Esteroides/metabolismo , Terpenos/isolamento & purificação , Fatores de Transcrição/genética , Fatores de Transcrição/metabolismo , Transfecção , Regulação para CimaRESUMO
PURPOSE: This study investigated the effect of the herbal medicine baicalin on bupropion hydroxylation, a probe reaction for CYP2B6 activity related to different CYP2B6 genotype groups. METHOD: Seventeen healthy male volunteers (6 CYP2B6*1/*1, 6 CYP2B6*1/*6, and 5 CYP2B6*6/*6) received orally administered bupropion alone and during daily treatment with baicalin. Blood samples were taken up to 72 h after each bupropion dose, and pharmacokinetics profiles were determined on days 1 and 25 for bupropion and hydroxybupropion. RESULT: Baicalin administration increased hydroxybupropion maximum plasma concentration (C(max)) by 73% [90% confidence interval (CI), 44-108%; P < 0.01] and the area under the concentration time curve extrapolated to infinity (AUC(0-infinity)) of hydroxybupropion by 87% (90% CI, 48-137%; P < 0.01), with no change in the elimination half-life of hydroxybupropion. Baicalin increased the AUC(0-infinity) ratio of hydroxybupropion to bupropion by 63% (90% CI, 38-92%; P < 0.01). CONCLUSION: Baicalin significantly induced CYP2B6-catalyzed bupropion hydroxylation, and the effects of baicalin on other CYP2B6 substrate drugs deserve further investigation.
Assuntos
Hidrocarboneto de Aril Hidroxilases/biossíntese , Hidrocarboneto de Aril Hidroxilases/efeitos dos fármacos , Bupropiona/análogos & derivados , Bupropiona/metabolismo , Flavonoides/farmacologia , Oxirredutases N-Desmetilantes/biossíntese , Oxirredutases N-Desmetilantes/efeitos dos fármacos , Extratos Vegetais/farmacologia , Adulto , Área Sob a Curva , Bupropiona/sangue , Bupropiona/farmacocinética , Citocromo P-450 CYP2B6 , Inibidores da Captação de Dopamina/metabolismo , Indução Enzimática/efeitos dos fármacos , Flavonoides/química , Glucuronidase/antagonistas & inibidores , Haplótipos , Interações Ervas-Drogas , Humanos , Hidroxilação/efeitos dos fármacos , Masculino , Extratos Vegetais/química , Polimorfismo de Nucleotídeo Único , Fatores de TempoRESUMO
Hops extracts are used to alleviate menopausal symptoms and as an alternative to hormone replacement therapy, but they can produce potentially harmful drug-drug interactions. The nuclear xenobiotic receptor pregnane X receptor (PXR) is promiscuously activated by a range of structurally distinct chemicals. It has a key role in the transcriptional regulation of genes that encode xenobiotic metabolism enzymes. In this study, hops extracts are shown to induce the expression of numerous drug metabolism and excretion proteins. The beta-bitter acid colupulone is demonstrated to be a bioactive component and direct activator of human PXR. The 2.8-A resolution crystal structure of the ligand binding domain of human PXR in complex with colupulone was elucidated, and colupulone was observed to bind in a single orientation stabilized by both van der Waals and hydrogen bonding contacts. The crystal structure also indicates that related alpha- and beta-bitter acids have the capacity to serve as PXR agonists as well. Taken together, these results reveal the structural basis for drug-drug interactions mediated by colupulone and related constituents of hops extracts.
Assuntos
Cicloexanonas/farmacologia , Humulus , Receptores de Esteroides/agonistas , Subfamília B de Transportador de Cassetes de Ligação de ATP , Membro 1 da Subfamília B de Cassetes de Ligação de ATP/biossíntese , Membro 1 da Subfamília B de Cassetes de Ligação de ATP/genética , Hidrocarboneto de Aril Hidroxilases/biossíntese , Sítios de Ligação , Cristalografia por Raios X , Cicloexanonas/química , Citocromo P-450 CYP2B6 , Citocromo P-450 CYP3A/biossíntese , Hepatócitos/efeitos dos fármacos , Hepatócitos/metabolismo , Humanos , Técnicas In Vitro , Oxirredutases N-Desmetilantes/biossíntese , Extratos Vegetais/química , Extratos Vegetais/farmacologia , Receptor de Pregnano X , RNA Mensageiro/biossíntese , Receptores de Esteroides/química , Regulação para CimaRESUMO
The pregnane X receptor (PXR, NR1I2) and the estrogen receptors (ERalpha, NR3A1 and ERbeta, NR3A2) bind a large number of compounds, including environmental pollutants and drugs, which exhibit remarkably diverse structural features. This prompted us to investigate if ER ligands could be PXR activators. We focused our attention on known estrogens from various chemical classes: physiological and synthetic estrogens and antiestrogens, plant and fungus estrogens, and other man-made chemicals belonging to phthalate plasticizers, surfactant-derived alkylphenols and cosmetics. Altogether, nearly 50 compounds were thus analyzed for their ability to activate human PXR in stably transfected cells, HGPXR cells, derived from HeLa cells and expressing luciferase under the control of a chimeric hPXR. Some of the newly identified hPXR activators were also checked for their ability to induce cytochrome P450 3A4 and 2B6 expressions in a primary culture of human hepatocytes. A significant proportion (54%) of compounds with estrogenic activity or able to bind ER were found to be hPXR activators: in particular, antiestrogens, mycoestrogens and phthalates. An even greater proportion is observed if estrogenic pesticides are included. Altogether, these results raise the question of the meaning and consequences of compounds with double PXR/ER activation ability.
Assuntos
Moduladores de Receptor Estrogênico/toxicidade , Estrogênios/toxicidade , Hepatócitos/efeitos dos fármacos , Receptores de Esteroides/metabolismo , Hidrocarboneto de Aril Hidroxilases/biossíntese , Linhagem Celular , Citocromo P-450 CYP2B6 , Citocromo P-450 CYP3A , Sistema Enzimático do Citocromo P-450/biossíntese , Congêneres do Estradiol/toxicidade , Hepatócitos/enzimologia , Hepatócitos/metabolismo , Humanos , Ligantes , Luciferases/metabolismo , Oxirredutases N-Desmetilantes/biossíntese , Fitoestrógenos/toxicidade , Receptor de Pregnano X , TransfecçãoRESUMO
We investigated the effect of Apocynum venetum L. extract (AV) on the activity of cytochrome P450 (CYP) 3A and P-glycoprotein (P-gp). The plasma concentration of nifedipine (NF), which is a substrate for CYP3A, did not change after oral administration with AV (3.3 mg/kg). Also, AV (3.3 and 33 mg/kg) did not affect the intestinal absorption of NF. In the rats treated with multiple administrations (15 mg/kg/d) of St. John's wort extract (SJW) for 2 weeks, the plasma concentration of NF after oral administration was significantly decreased. On the other hand, there was no significant differences in the pharmacokinetic parameters of NF between AV-treated (3.3 mg/kg/d) and none-treated rats. Furthermore, the intestinal absorption of methylprednisolone, which is a substrate for P-gp, was not affected by AV treatment for 2 weeks. These results suggest that, unlike SJW, the recommended dose of AV (3.3 mg/kg/d) would not influence hepatic CYP3A and intestinal P-gp in rats.
Assuntos
Membro 1 da Subfamília B de Cassetes de Ligação de ATP/biossíntese , Apocynum , Hidrocarboneto de Aril Hidroxilases/biossíntese , Oxirredutases N-Desmetilantes/biossíntese , Animais , Citocromo P-450 CYP3A , Interações Ervas-Drogas , Hypericum , Técnicas In Vitro , Absorção Intestinal , Masculino , Metilprednisolona/farmacocinética , Nifedipino/farmacocinética , Extratos Vegetais/farmacologia , Ratos , Ratos WistarRESUMO
Gugulipid is an extract of the guggul tree, Commiphora mukul, that is used to treat hyperlipidemia in humans. The lipid-lowering activity is found in the stereoisomers and plant sterols Z-guggulsterone and E-guggulsterone. The molecular basis for the lipid-lowering action of guggulsterone has been suggested to be antagonism of the farnesoid X receptor, a member of the nuclear receptor superfamily of ligand-activated transcription factors. To determine whether guggulsterone has the ability to function as an agonist of other nuclear receptor family members, we screened a panel of these proteins for their ability to transactivate reporter genes. Here, we show that guggulsterones activate the estrogen receptor alpha isoform, progesterone receptor, and pregnane X receptor. Concentration-response analysis using reporter gene assays indicate that guggulsterones activate these three receptors with EC(50) values in the low micromolar range. Furthermore, we show that guggulsterone-mediated activation of the pregnane X receptor induces the expression of CYP3A genes in both rodent and human hepatocytes. Protein interaction assays indicate that guggulsterones interact directly with pregnane X receptor, thereby modulating interaction with protein cofactors. We introduce a novel method to screen herbal remedies for their ability to activate pregnane X receptor. Pregnane X receptor activation is known to cause herb-drug interactions, and our data suggest that gugulipid therapy should be used cautiously in patients taking prescription medications that are metabolized by CYP3A family members. Moreover, our data suggest the need for additional studies of guggulsterones agonist activity against estrogen receptor alpha isoform and the progesterone receptor.
Assuntos
Hidrocarboneto de Aril Hidroxilases/biossíntese , Hidrocarboneto de Aril Hidroxilases/genética , Oxirredutases N-Desmetilantes/biossíntese , Oxirredutases N-Desmetilantes/genética , Pregnenodionas/farmacologia , Receptores Citoplasmáticos e Nucleares/fisiologia , Receptores de Esteroides/fisiologia , Animais , Citocromo P-450 CYP3A , Relação Dose-Resposta a Droga , Ativação Enzimática/efeitos dos fármacos , Ativação Enzimática/fisiologia , Humanos , Camundongos , Camundongos Knockout , Receptor de Pregnano X , Receptores Citoplasmáticos e Nucleares/agonistas , Receptores de Esteroides/agonistasRESUMO
The aim was to characterize mouse gender and strain differences in the metabolism of commonly used human cytochrome (CYP) P450 probe substrates. Thirteen human CYP probe substrates (phenacetin, coumarin, 7-ethoxy-4-trifluoromethyl coumarin, amiodarone, paclitaxel, diclofenac, S-mephenytoin, bufuralol, dextromethorphan, chlorzoxazone, p-nitrophenol, testosterone and lauric acid) were used in activity measurements. The metabolism of the probe substrates was compared in liver microsomes from male and female NMRI, CBA, C57bl/6, 129/SvJ and CD1 strains. The expression of proteins identified on Western blots with commonly available antibodies selective for specific human and rat CYP enzymes were compared in the different mouse strains. Males had higher metabolism than corresponding females for phenacetin O-deethylation (human marker for CYP1A2 activity), and a high correlation was found between phenacetin activity and immunoreactivity in Western blots produced with rat CYP1A2 antibodies. Protein detected by antibodies cross-reacting with human CYP2B6 and rat CYP2B1/2 antibodies was female specific except for the 129/SvJ strain, where it was absent in both genders. Females generally had a higher metabolism of bufuralol 1'-hydroxylation and dextromethorphan O-demethylation (human markers for CYP2D activity). Bufuralol 1'-hydroxylation correlated with a female-dominant mouse CYP, which was detected with antibodies against rat CYP2D4. p-Nitrophenol 2-hydroxylation correlated better than chlorzoxazone 6-hydroxylation with the protein detected with antibodies against rat CYP2E1, indicating that p-nitrophenol is a more specific substrate for mouse CYP2E1.
Assuntos
Sistema Enzimático do Citocromo P-450/metabolismo , Amiodarona/metabolismo , Animais , Hidrocarboneto de Aril Hidroxilases/biossíntese , Western Blotting , Clorzoxazona/metabolismo , Cumarínicos/metabolismo , Citocromo P-450 CYP1A2/biossíntese , Citocromo P-450 CYP2B6 , DNA Complementar/metabolismo , Dextrometorfano/metabolismo , Diclofenaco/metabolismo , Etanolaminas/metabolismo , Feminino , Humanos , Cinética , Ácidos Láuricos/metabolismo , Masculino , Mefenitoína/metabolismo , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Endogâmicos CBA , Microssomos Hepáticos , Oxigenases de Função Mista/biossíntese , NADP/metabolismo , Nitrofenóis/metabolismo , Oxirredutases N-Desmetilantes/biossíntese , Oxigênio/metabolismo , Paclitaxel/metabolismo , Fenacetina/metabolismo , Ratos , Fatores Sexuais , Especificidade da Espécie , Especificidade por Substrato , Testosterona/metabolismoRESUMO
OBJECTIVES: The popular herbal remedy St John's wort is an inducer of cytochrome P450 (CYP) 3A enzymes and may reduce the efficacy of oral contraceptives. Therefore we evaluated the effect of St John's wort on the disposition and efficacy of Ortho-Novum 1/35 (Ortho-McNeil Pharmaceutical, Inc, Raritan, NJ), a popular combination oral contraceptive pill containing ethinyl estradiol (INN, ethinylestradiol) and norethindrone (INN, norethisterone). METHODS: Twelve healthy premenopausal women who were using oral contraception (>3 months) received a combination oral contraceptive pill (Ortho-Novum 1/35) for 3 consecutive 28-day menstrual cycles. During the second and third cycles, the participants received 300 mg St John's wort 3 times a day. The serum concentrations of ethinyl estradiol (day 7), norethindrone (day 7), follicle-stimulating hormone (days 12-16), luteinizing hormone (days 12-16), progesterone (day 21), and intravenous and oral midazolam (days 22 and 23) were determined in serial blood samples. The incidence of breakthrough bleeding was quantified during the first and third cycles. RESULTS: Concomitant use of St John's wort was associated with a significant (P <.05) increase in the oral clearance of norethindrone (8.2 +/- 2.7 L/h to 9.5 +/- 3.4 L/h, P =.042) and a significant reduction in the half-life of ethinyl estradiol (23.4 +/- 19.5 hours to 12.2 +/- 7.1 hours, P =.023). The oral clearance of midazolam was significantly increased (109.2 +/- 47.9 L/h to 166.7 +/- 81.3 L/h, P =.007) during St John's wort administration, but the systemic clearance of midazolam was unchanged (37.7 +/- 11.3 L/h to 39.0 +/- 10.3 L/h, P =.567). Serum concentrations of follicle-stimulating hormone, luteinizing hormone, and progesterone were not significantly affected by St John's wort dosing (P >.05). Breakthrough bleeding occurred in 2 of 12 women in the control phase compared with 7 of 12 women in the St John's wort phase. The oral clearance of midazolam after St John's wort dosing was greater in women who had breakthrough bleeding (215.9 +/- 66.5 L/h) than in those who did not (97.5 +/- 37.2 L/h) (P =.005). CONCLUSION: St John's wort causes an induction of ethinyl estradiol-norethindrone metabolism consistent with increased CYP3A activity. Women taking oral contraceptive pills should be counseled to expect breakthrough bleeding and should consider adding a barrier method of contraception when consuming St Johns wort.
Assuntos
Hidrocarboneto de Aril Hidroxilases/biossíntese , Anticoncepcionais Orais Combinados/metabolismo , Indução Enzimática/efeitos dos fármacos , Hypericum , Hipnóticos e Sedativos/farmacocinética , Mestranol/metabolismo , Midazolam/farmacocinética , Noretindrona/metabolismo , Oxirredutases N-Desmetilantes/biossíntese , Preparações de Plantas/farmacologia , Administração Oral , Adulto , Área Sob a Curva , Hidrocarboneto de Aril Hidroxilases/metabolismo , Anticoncepcionais Orais Combinados/sangue , Anticoncepcionais Orais Combinados/farmacocinética , Citocromo P-450 CYP3A , Combinação de Medicamentos , Interações Medicamentosas , Feminino , Hormônio Foliculoestimulante/sangue , Meia-Vida , Humanos , Injeções Intravenosas , Ciclo Menstrual/efeitos dos fármacos , Mestranol/farmacocinética , Taxa de Depuração Metabólica , Noretindrona/farmacocinética , Oxirredutases N-Desmetilantes/metabolismo , Preparações de Plantas/administração & dosagemRESUMO
The pregnane X receptor (PXR), which is a member of the nuclear receptor family of ligand-activated transcription factors, is an integral component of the body's defense mechanism against toxic xenobiotics. PXR is activated by a broad spectrum of lipophilic xenobiotics including prescription drugs, herbs, pesticides, endocrine disruptors and other environmental contaminants. The promiscuous ligand-binding properties of PXR are facilitated by the large volume and smooth shape of its ligand-binding pocket. PXR binds to DNA as a heterodimer with the 9-cis retinoic acid receptor (RXR) and regulates a large number of genes involved in the detoxification and excretion of toxic substances. Although PXR evolved to protect the body, its activation by various prescription drugs and herbs such as St. John's wort represents the molecular basis for an important class of drug-drug interactions. Assays that detect PXR activation can now be used to predict and prevent these drug-drug interactions.
Assuntos
Hidrocarboneto de Aril Hidroxilases/biossíntese , Inativação Metabólica , Oxirredutases N-Desmetilantes/biossíntese , Receptores Citoplasmáticos e Nucleares , Receptores de Esteroides , Xenobióticos , Animais , Sítios de Ligação , Citocromo P-450 CYP3A , Interações Medicamentosas , Indução Enzimática , Humanos , Hypericum/fisiologia , Receptor de Pregnano X , Receptores Citoplasmáticos e Nucleares/genética , Receptores Citoplasmáticos e Nucleares/metabolismo , Receptores Citoplasmáticos e Nucleares/fisiologia , Receptores de Esteroides/genética , Receptores de Esteroides/metabolismo , Receptores de Esteroides/fisiologia , Xenobióticos/efeitos adversos , Xenobióticos/antagonistas & inibidores , Xenobióticos/metabolismoRESUMO
A series of N-hydroxyformamide tumor necrosis factor-alpha converting enzyme (TACE)/matrix metalloprotease (MMP) inhibitors were evaluated for their potential to induce human cytochrome P450 3A (CYP3A). Two in vitro assays were used: 1) a cell-based reporter gene assay for activation of the pregnane X receptor (PXR), and 2) a primary "sandwich" culture of human hepatocytes. Approximately 50 TACE/MMP inhibitors were evaluated in the human PXR assay. A range of PXR activation was observed, 0 to 150% of the activation of the known human CYP3A inducer rifampicin. Three TACE/MMP inhibitors were evaluated in rat and human hepatocytes. Significantly higher PXR activation/CYP3A induction was observed in PXR/hepatocyte models, respectively, for (2R,3S) 3-(formyl-hydroxyamino)-2-(2-methyl-1-propyl)-4-methylpentanoic acid [(1S,2S)-2-methyl-1-(2-pyridylcarbamoyl)-1-butyl]amide (GW3333) compared with (2R,3S)-6,6,6-trifluoro-3-[formyl(hydroxy)amino]-2-isobutyl-N-[(1S,2R)-2-methoxy-1-[(1,3-thiazol-2-ylamino)carbonyl]propyl]hexanamide (GW6495) and (2R)-N-[(1S)-2,2-dimethyl-1-[(methylamino)carbonyl]-propyl]-2-[(1S)-1-[formyl(hydroxy)amino]ethyl]-5-phenylpentanamide (GI4023). The CYP3A induction level achieved with GW3333 at a concentration of approximately 10 microM in human hepatocytes was comparable to that achieved with rifampicin at a concentration of 10 microM. The extent of rodent CYP3A induction caused by GW3333 was confirmed in vivo after daily oral administration for 14 days to rats. In conclusion, GW3333 is a potential inducer of CYP3A expression in vivo in humans, but other N-hydroxyformamides are less likely to induce CYP3A.
Assuntos
Hidrocarboneto de Aril Hidroxilases/biossíntese , Formamidas/farmacologia , Hepatócitos/efeitos dos fármacos , Inibidores de Metaloproteinases de Matriz , Metaloendopeptidases/antagonistas & inibidores , Oxirredutases N-Desmetilantes/biossíntese , Receptores Citoplasmáticos e Nucleares/metabolismo , Receptores de Esteroides/metabolismo , Proteínas ADAM , Proteína ADAM17 , Administração Oral , Amidas/administração & dosagem , Amidas/farmacocinética , Aminopiridinas/administração & dosagem , Aminopiridinas/sangue , Aminopiridinas/farmacocinética , Animais , Hidrocarboneto de Aril Hidroxilases/efeitos dos fármacos , Técnicas de Cultura de Células , Citocromo P-450 CYP3A , Dipeptídeos/administração & dosagem , Dipeptídeos/sangue , Dipeptídeos/farmacocinética , Relação Dose-Resposta a Droga , Avaliação de Medicamentos , Avaliação Pré-Clínica de Medicamentos , Indução Enzimática , Formamidas/química , Hepatócitos/metabolismo , Humanos , Masculino , Metaloproteinases da Matriz/administração & dosagem , Metaloproteinases da Matriz/farmacocinética , Oxirredutases N-Desmetilantes/efeitos dos fármacos , Receptor de Pregnano X , Ratos , Ratos Wistar , Receptores Citoplasmáticos e Nucleares/efeitos dos fármacos , Receptores de Esteroides/efeitos dos fármacos , Tiazóis/administração & dosagem , Tiazóis/farmacocinéticaRESUMO
BACKGROUND: Many drugs are cosubstrates of cytochrome P450 (CYP) 3A and MDR1; furthermore, their disposition is markedly affected by pretreatment with inducing agents, including St John's wort. Such drug interactions reflect induction of both proteins through a common mechanism involving the steroid X receptor/pregnane X receptor. However, the relative contributions of enhanced metabolism and efflux transport to the overall induction process are unknown. METHODS: The effects of 12 days' pretreatment with St John's wort on the disposition of selected in vivo probe drugs were determined in 21 young healthy subjects. Midazolam after oral and intravenous administration was used to assess CYP3A activity in both the intestinal epithelium and the liver, whereas the disposition of fexofenadine after an oral dose was assumed to be a measure of MDR1 function, and the oral plasma concentration-time profile of cyclosporine (INN, ciclosporin) was considered to reflect both CYP3A and MDR1 activities. RESULTS: St John's wort markedly affected the plasma concentration-time profiles of all of the drugs, with associated increases in their clearance. With midazolam, the enhancement was considerably less after intravenous administration (approximately 1.5-fold) than after oral administration (approximately 2.7-fold), and estimated intestinal and hepatic extraction ratios were higher by approximately 1.2- to 1.4-fold. By contrast, the oral clearances of fexofenadine and cyclosporine were equally increased by approximately 1.6-fold and 1.9-fold, respectively; these changes were both statistically less than for midazolam's oral clearance and greater than its estimated intestinal extraction. CONCLUSIONS: Although the disposition of all 3 drugs was altered by St John's wort, the extent of induction measured by oral clearance was different with CYP3A activity (midazolam), apparently increasing more than MDR1 function (fexofenadine), whereas with cyclosporine the change in oral clearance appeared to be more closely associated with the increase in MDR1 rather than CYP3A, despite the fact that both proteins are importantly involved in its disposition. These discordances indicate that, although a common molecular mechanism may be involved, the quantitative aspects of induction are complex and depend on the particular drug and the relative contributions of CYP3A and MDR1 in its disposition.
Assuntos
Hidrocarboneto de Aril Hidroxilases/biossíntese , Genes MDR/efeitos dos fármacos , Hypericum , Oxirredutases N-Desmetilantes/biossíntese , Preparações de Plantas/farmacologia , Terfenadina/análogos & derivados , Adulto , Hidrocarboneto de Aril Hidroxilases/metabolismo , Estudos Cross-Over , Ciclosporina/farmacocinética , Citocromo P-450 CYP3A , Esquema de Medicação , Indução Enzimática/efeitos dos fármacos , Feminino , Regulação da Expressão Gênica/efeitos dos fármacos , Humanos , Mucosa Intestinal/efeitos dos fármacos , Mucosa Intestinal/enzimologia , Fígado/efeitos dos fármacos , Fígado/enzimologia , Masculino , Midazolam/farmacocinética , Pessoa de Meia-Idade , Oxirredutases N-Desmetilantes/metabolismo , Preparações de Plantas/administração & dosagem , Valores de Referência , Terfenadina/farmacocinéticaRESUMO
OBJECTIVE: We investigated the effects of treatment with Saint John's wort (hypericum perforatum) extract on the urinary excretion of D-glucaric acid, 6beta-hydroxycortisol, and free cortisol in order to assess the effect of this extract on the activity of hepatic xenobiotic metabolizing enzymes. METHODS: Forty-eight healthy volunteers (25 male and 23 female) received a daily dose of 1800 mg hypericum extract for 14 days. Urinary excretion of D-glucaric acid, 6beta-hydroxycortisol, and free cortisol was measured in 24-h urine samples on the day preceding the initiation of hypericum treatment and after 14 days of treatment. D-Glucaric acid was measured enzymatically. Cortisol and 6beta-hydroxycortisol were quantified using high-performance liquid chromatography with ultraviolet detection. RESULTS: Urinary excretion of D-glucaric acid was unaffected after a 14-day treatment with Saint John's wort extract (26.7 micromol/day vs 27.7 micromol/day; 95% confidence interval of the difference: -1.9 to 3.8). The urinary excretion of 6beta-hydroxycortisol increased from a mean baseline value of 254 microg/day to 369 microg/day (P<0.0001) indicating induction of CYP3A. While the excretion of free cortisol was unaltered, the ratio of 6beta-hydroxycortisol to free cortisol changed significantly from 9.9 at baseline to 14.3 (95% confidence interval of the difference: 2.3-6.5) after Saint John's wort treatment. CONCLUSIONS: High-dose treatment with Saint John's wort extract induced CYP3A activity in healthy volunteers as evidenced by increased 6beta-hydroxycortisol excretion. This enzyme induction most likely contributes to the decreased bioavailability observed upon co-administration of various drugs with Saint John's wort extract. The D-glucuronic acid pathway appeared unaffected by Saint John's wort.
Assuntos
Ácido Glucárico/urina , Hidrocortisona/análogos & derivados , Hidrocortisona/urina , Hypericum/química , Adulto , Hidrocarboneto de Aril Hidroxilases/biossíntese , Citocromo P-450 CYP3A , Indução Enzimática , Feminino , Humanos , Masculino , Oxirredutases N-Desmetilantes/biossíntese , Extratos Vegetais/farmacologiaRESUMO
California poppy (Eschscholzia californica Cham.) cell cultures produce several benzophenanthridine alkaloids, such as sanguinarine, chelirubine, and macarpine, with potent pharmacological activity. Antisense constructs of genes encoding two enzymes involved in benzophenanthridine alkaloid biosynthesis, the berberine bridge enzyme (BBE) and N-methylcoclaurine 3'-hydroxylase (CYP80B1), were introduced separately into California poppy cell cultures. Transformed cell lines expressing antisense BBE or antisense CYP80B1 constructs and displaying low levels of BBE or CYP80B1 mRNAs, respectively, showed reduced accumulation of benzophenanthridine alkaloids compared with control cultures transformed with a beta-glucuronidase gene. Pathway intermediates were not detected in any of the transformed cell lines. The suppression of benzophenanthridine alkaloid biosynthesis using BBE or CYP80B1 antisense RNA constructs also reduced the growth rate of the cultures. Two-dimensional (1)H-nuclear magnetic resonance and in vivo (15)N-nuclear magnetic resonance spectroscopy showed no difference in the abundance of carbohydrate metabolites in the various transgenic cell lines. However, transformed cells with reduced benzophenanthridine alkaloid levels contained larger cellular pools of several amino acids including alanine, leucine, phenylalanine, threonine, and valine compared with controls. The relative abundance of tyrosine, from which benzophenanthridine alkaloids are derived, was less than 2-fold higher in antisense-suppressed cells relative to controls. These results show that alterations in the metabolic flux through benzophenanthridine alkaloid biosynthesis can affect the regulation of amino acid pools. These data provide new insight into the metabolic engineering of benzophenanthridine alkaloid pathways.
Assuntos
Alcaloides/isolamento & purificação , Sistema Enzimático do Citocromo P-450/genética , Oxigenases de Função Mista/genética , Oxirredutases N-Desmetilantes/genética , Papaver/enzimologia , Fenantridinas/metabolismo , Alcaloides/química , Aminoácidos/metabolismo , Benzofenantridinas , Células Cultivadas , Sistema Enzimático do Citocromo P-450/biossíntese , Expressão Gênica , Isoquinolinas , Marcação por Isótopo , Espectroscopia de Ressonância Magnética , Oxigenases de Função Mista/biossíntese , Oxirredutases N-Desmetilantes/biossíntese , Papaver/química , Papaver/genética , Fenantridinas/química , Fenantridinas/isolamento & purificação , Extratos Vegetais/química , Extratos Vegetais/isolamento & purificação , Proteínas de Plantas , Plantas Geneticamente Modificadas/genética , RNA Antissenso/genéticaRESUMO
This investigation was designed to determine the ability of St. John's wort (SJW), a readily available antidepressant, to induce various hepatic drug metabolizing enzymes. SJW (140 or 280 mg/kg/day) was administered to male Swiss Webster mice for 1, 2, or 3 weeks. Enzymatic activity was analyzed in hepatic microsomes for all of the following drug metabolizing enzymes: CYP3A, CYP1A, CYP2E1, and UDP-glucuronosyltransferase (UDPGT). The catalytic activity of CYP1A was unchanged from control following any dose or duration of SJW, while both CYP3A and CYP2E1 catalytic activities were increased 2-fold by both SJW concentrations but only following 3 weeks of administration. Results from Western immunoblotting studies supported the changes in catalytic activity, as protein levels for CYP2E1 and CYP3A were increased (2.5-fold and 6-fold, respectively) following 3 weeks of SJW administration. Additionally, the catalytic activity of the conjugation enzyme UDPGT was unchanged from control following all SJW treatments. These results indicate that in the mouse moderate doses of SJW cause an increase in the catalytic activity and polypeptide levels of CYP2E1 and CYP3A but only following 21 days of administration, while the catalytic activity of CYP1A and UDPGT activity remain unaffected.
Assuntos
Hidrocarboneto de Aril Hidroxilases , Citocromo P-450 CYP2E1/biossíntese , Sistema Enzimático do Citocromo P-450/biossíntese , Hypericum , Fígado/efeitos dos fármacos , Oxirredutases N-Desmetilantes/biossíntese , Extratos Vegetais/farmacologia , Animais , Western Blotting , Peso Corporal/efeitos dos fármacos , Citocromo P-450 CYP1A2/biossíntese , Citocromo P-450 CYP3A , Relação Dose-Resposta a Droga , Indução Enzimática/efeitos dos fármacos , Glucuronosiltransferase/biossíntese , Fígado/enzimologia , Fígado/crescimento & desenvolvimento , Masculino , Camundongos , Camundongos Endogâmicos , Microssomos Hepáticos/efeitos dos fármacos , Microssomos Hepáticos/enzimologia , Tamanho do Órgão/efeitos dos fármacos , Extratos Vegetais/sangue , Fatores de TempoRESUMO
BACKGROUND: St John's wort (Hypericum perforatum) is a popular over-the-counter dietary supplement and herbal remedy that has been implicated in drug interactions with substrates of several cytochrome P450 (CYP) isozymes. The effect of St John's wort on CYP activity in vivo was examined with a probe drug cocktail. METHODS: Twelve healthy subjects (5 female, 7 male) completed this 3-period, open-label, fixed schedule study. Tolbutamide (CYP2C9), caffeine (CYP1A2), dextromethorphan (CYP2D6), oral midazolam (intestinal wall and hepatic CYP3A), and intravenous midazolam (hepatic CYP3A) were administered before, with short-term St John's wort dosing (900 mg), and after 2 weeks of intake (300 mg 3 times a day) to determine CYP activities. RESULTS: Short-term administration of St John's wort had no effect on CYP activities. Long-term St John's wort administration caused a significant (P <.05) increase in oral clearance of midazolam from 121.8 +/- 70.7 to 254.5 +/- 127.8 and a corresponding significant decline in oral bioavailability from 0.28 +/- 0.15 to 0.17 +/- 0.06. In contrast to the >50% decrease in the area under the plasma concentration-time curve (AUC) when midazolam was administered orally, long-term St John's wort administration caused a 20% decrease in AUC when midazolam was given intravenously. There was no change in CYP1A2, CYP2C9, or CYP2D6 activities as a result of St John's wort administration. CONCLUSION: Long-term St John's wort administration resulted in a significant and selective induction of CYP3A activity in the intestinal wall. St John's wort did not alter the CYP2C9, CYP1A2, or CYP2D6 activities. Reduced therapeutic efficacy of drugs metabolized by CYP3A should be anticipated during long-term administration of St John's wort.
Assuntos
Hidrocarboneto de Aril Hidroxilases , Sistema Enzimático do Citocromo P-450/biossíntese , Suplementos Nutricionais , Hypericum , Midazolam/farmacocinética , Administração Oral , Adulto , Área Sob a Curva , Disponibilidade Biológica , Cafeína/farmacocinética , Cafeína/farmacologia , Citocromo P-450 CYP3A , Inibidores das Enzimas do Citocromo P-450 , Dextrometorfano/farmacocinética , Dextrometorfano/farmacologia , Interações Medicamentosas , Indução Enzimática/efeitos dos fármacos , Feminino , Humanos , Injeções Intravenosas , Isoenzimas/antagonistas & inibidores , Isoenzimas/biossíntese , Masculino , Midazolam/administração & dosagem , Oxirredutases N-Desmetilantes/biossíntese , Extratos Vegetais/administração & dosagem , Extratos Vegetais/farmacologia , Tolbutamida/farmacocinética , Tolbutamida/farmacologiaRESUMO
An experimental model of porphyria cutanea tarda (PCT) can be achieved in 3 weeks by a single injection of a mixture of polychlorinated biphenyls (Aroclor 1254) into iron-loaded female Fischer 344 rats maintained continuously on delta-aminolevulinic acid-supplemented drinking water. In this model, daily treatment with 5-pregnen-3 beta-ol-20-one-16 alpha-carbonitrile (pregnenolone 16 alpha-carbonitrile) attenuated uroporphyrin and heptacarboxylporphyrin accumulation and excretion by 75%. Pregnenolone 16 alpha-carbonitrile treatment had only a minor effect on hepatic iron stores, and it had no effect on the induction of CYP1A activities by Aroclor 1254. In the absence of Aroclor 1254, pregnenolone 16 alpha-carbonitrile had no effect on the accumulation and excretion of highly carboxylated porphyrins. Attenuation of porphyrin accumulation could also be demonstrated with daily troleandomycin treatment. Troleandomycin increased CYP3A-dependent erythromycin demethylase activity, but to a lesser extent than pregnenolone 16 alpha-carbonitrile. Much of the CYP3A induced by troleandomycin was sequestered as a catalytically inactive metabolic-intermediate complex. In the absence of Aroclor 1254, troleandomycin had no effect on the accumulation and excretion of highly carboxylated porphyrins, nor did troleandomycin alter the induction of CYP1A by Aroclor 1254. The results suggest that the major attenuation of hepatic accumulation and urinary excretion of uro- and heptacarboxylporphyrins in the rat PCT model by pregnenolone 16 alpha-carbonitrile and troleandomycin is due to an enhancement of CYP3A catalytic activity.
Assuntos
Hidrocarboneto de Aril Hidroxilases , Sistema Enzimático do Citocromo P-450/biossíntese , Oxirredutases N-Desmetilantes/biossíntese , Porfiria Cutânea Tardia/metabolismo , Troleandomicina/farmacologia , Uroporfirinas/metabolismo , Animais , Antibacterianos/farmacologia , Citocromo P-450 CYP3A , Sistema Enzimático do Citocromo P-450/efeitos dos fármacos , Modelos Animais de Doenças , Indução Enzimática , Feminino , Oxirredutases N-Desmetilantes/efeitos dos fármacos , Carbonitrila de Pregnenolona/farmacologia , Ratos , Ratos Endogâmicos F344RESUMO
The catalytic properties of CYP3A7 in the metabolism of endogenous and exogenous substrates were compared with those of CYP3A4 and CYP3A5 using COS-7 expressing enzymes. The highest activities of dehydroepiandrosterone (DHEA) and dehydroepiandrosterone 3-sulfate (DHEA-S) 16alpha-hydroxylase were observed in COS-7 cells expressing CYP3A7. In contrast, the activity of testosterone 6beta-hydroxylase of CYP3A7 expressed in COS-7 cells was much less than that of CYP3A4 expressed in COS-7 cells. The rate of carbamazepine 10, 11-epoxidation was the greatest in COS-7 cells expressing CYP3A4, followed by CYP3A5 and CYP3A7. On the other hand, the formation of reductive metabolite of zonisamide was the highest in COS-7 cells expressing CYP3A4, followed by CYP3A7 and CYP3A5. Furthermore, the addition of triazolam resulted in a decrease in 6beta-hydroxylation catalyzed by CYP3A7, but not by CYP3A4, whereas the pretreatment of microsomes with triacetyloleandomycin (TAO) resulted in a decrease in the reaction catalyzed by CYP3A4, but not by CYP3A7. Together with these results, it was suggested that CYP3A7 exerts differential catalytic properties not only in metabolism of endogenous substrates but also in drug metabolism compared to CYP3A4 and CYP3A5.
Assuntos
Hidrocarboneto de Aril Hidroxilases , Sistema Enzimático do Citocromo P-450/biossíntese , Sistema Enzimático do Citocromo P-450/metabolismo , Oxirredutases N-Desmetilantes/biossíntese , Oxirredutases N-Desmetilantes/metabolismo , Adulto , Animais , Células COS , Catálise , Citocromo P-450 CYP3A , Sistema Enzimático do Citocromo P-450/análise , Sistema Enzimático do Citocromo P-450/genética , DNA Complementar/genética , Desidroepiandrosterona/metabolismo , Ativação Enzimática/efeitos dos fármacos , Vetores Genéticos/metabolismo , Humanos , Oxigenases de Função Mista/metabolismo , Oxirredutases N-Desmetilantes/genética , Esteroide 16-alfa-Hidroxilase , Esteroide Hidroxilases/metabolismo , Especificidade por Substrato , Testosterona/metabolismo , Transfecção , Triazolam/farmacologia , Troleandomicina/farmacologiaRESUMO
A genomic clone, bbe1 was isolated that encodes the methyl jasmonate-inducible berberine bridge enzyme of antimicrobial benzophenanthridine alkaloid biosynthesis in the California poppy Eschscholzia californica. Genomic DNA gel blot analysis indicates that two genes are present in the E. californica genome that code for the berberine bridge enzyme reading frame. Each coding region is apparently preceeded by a unique promoter sequence. The bbe1 gene contains no introns and one transcriptional start site. A 41 nucleotide region between -496 and -455 of the 5'-flanking region appears to be essential for promoter activity in E. californica. The promoter displayed an unexpectedly high species specificity, being active in only E. californica and Thalictrum bulgaricum, out of 28 cell suspension cultures tested.
Assuntos
Genes de Plantas , Oxirredutases N-Desmetilantes/genética , Papaver/enzimologia , Papaver/genética , Plantas Medicinais , Sequência de Aminoácidos , Sequência de Bases , California , Clonagem Molecular , Genoma de Planta , Dados de Sequência Molecular , Oxirredutases N-Desmetilantes/biossíntese , Proteínas Recombinantes/biossínteseRESUMO
1. The in vitro metabolism of n-hexane was studied in rat liver, lung, brain and skeletal muscle microsomes and in microsomes prepared from cell lines expressing human cytochrome P-450 2E1 or 2B6. The hydroxylated metabolites of n-hexane were quantified by gas chromatography-mass spectometry. 2. Rat liver and extensor digitorum longus (EDL, fast-twitch skeletal muscle) microsomes and the CYP 2B6 microsomes produced the pre-neurotoxic metabolite of n-hexane, 2-hexanol as a major metabolite in contrast to the other rat tissues examined. 3. Inhibition of 2- and 3-hexanol production from n-hexane by rat lung microsomes using metyrapone, an inhibitor of cytochrome P-450 2B1 activity, resulted in almost complete inhibition of lung microsomal activity. 4. Production of all three hexanols was significantly increased with phenobarbital-induced rat liver microsomes, with a 10-fold increase in 2- and 3-hexanol production. A slight increase in 2-hexanol production with phenobarbital-induced rat EDL and brain microsomes was observed. No increase in n-hexane metabolism was noted following induction with beta-naphthoflavone or with ethanol.
Assuntos
Hidrocarboneto de Aril Hidroxilases , Encéfalo/metabolismo , Sistema Enzimático do Citocromo P-450/biossíntese , Hexanos/metabolismo , Fígado/metabolismo , Pulmão/metabolismo , Músculo Esquelético/metabolismo , Animais , Encéfalo/efeitos dos fármacos , Encéfalo/enzimologia , Linhagem Celular , Óleo de Milho/farmacologia , Citocromo P-450 CYP2B6 , Citocromo P-450 CYP2E1/biossíntese , Inibidores do Citocromo P-450 CYP2E1 , Inibidores das Enzimas do Citocromo P-450 , Indução Enzimática/efeitos dos fármacos , Inibidores Enzimáticos/farmacologia , Etanol/farmacologia , Hexanóis/metabolismo , Humanos , Fígado/efeitos dos fármacos , Fígado/enzimologia , Pulmão/efeitos dos fármacos , Pulmão/enzimologia , Masculino , Metirapona/farmacologia , Microssomos/efeitos dos fármacos , Microssomos/enzimologia , Microssomos/metabolismo , Microssomos Hepáticos/efeitos dos fármacos , Microssomos Hepáticos/enzimologia , Microssomos Hepáticos/metabolismo , Músculo Esquelético/efeitos dos fármacos , Músculo Esquelético/enzimologia , Oxirredutases N-Desmetilantes/antagonistas & inibidores , Oxirredutases N-Desmetilantes/biossíntese , Fenobarbital/farmacologia , Distribuição Aleatória , Ratos , Ratos Wistar , beta-Naftoflavona/farmacologiaRESUMO
Studies on the modulation of the carcinogen metabolizing enzymes on treatment with masheri extract (ME) and benzo (a) pyrene (B (a)P), were carried out in male Sprague Dawley rats (12 weeks old) fed a nutritionally adequate standard diet. Injection (ip) of ME and B (a) P at 3/4 LD50 dose given in 3 doses at 24 hr interval increased the phase I activating enzymes, viz. cytochrome P-450, benzo (a) pyrene hydroxylase and benzphetamine demethylase while both ME and B (a) P significantly depleted glutathione content and decreased glutathione-S transferase activity. Furthermore, the same treatment of ME and B (a) P significantly depleted the hepatic vitamin A pool while a concommittant increase in vitamin C content was observed.